| Dianna Lynn Mahoney, MD | |
|
200 W. Hospital Drive, Whiteriver, AZ 85941-0860 | |
| (928) 338-4911 | |
| (928) 338-3522 |
| Full Name | Dianna Lynn Mahoney |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 27 Years |
| Location | 200 W. Hospital Drive, Whiteriver, Arizona |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1649372004 | NPI | - | NPPES |
| 618514 | Medicaid | AZ | |
| 1629236716 | Medicaid | AZ | |
| 1780614008 | Medicaid | AZ | |
| 1871523191 | Medicaid | AZ | |
| 1295993376 | Medicaid | AZ |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 27347 (Arizona) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Whiteriver Phs Indian Hospital | Whiteriver, AZ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Dhhs Ihs Phoenix Area | 2668649567 | 63 |
News Archive
Children may have a better quality of life (QOL) and diminished cardiovascular disease risk from the decreased endothelin 1 (ET-1) levels after adenotonsillectomy, according to new research published in the December 2011 issue of Otolaryngology - Head and Neck Surgery.
ARIUS Research Inc has announced that the Company has initiated the first study in the formal pre-clinical toxicology program for its lead anti-CD44 drug candidate, which is under development for the treatment of breast, prostate and liver cancers.
According to a new survey most people at high risk of Alzheimer's disease would be willing to have their loved ones enroll them in research studies when they could no longer give consent themselves.
Roche and study investigators from Harvard University and Massachusetts General Hospital announced today that in the PROTECT (Pro-BNP Outpatient Tailored Chronic HF Therapy) trial, a strategy of NT-proBNP guided heart failure care was independently associated with a significant reduction in total cardiovascular events, the primary composite endpoint of the study, which included worsening heart failure, heart failure hospitalization and cardiovascular related death
Santen Pharmaceutical Co., Ltd. and Inspire Pharmaceuticals, Inc. announced today that the Japanese Ministry of Health, Labour and Welfare granted approval for the new dry eye treatment drug, DIQUAS Ophthalmic Solution 3% (generic name: diquafosol tetrasodium), on April 16, 2010.
› Verified 5 days ago
| Entity Name | Dhhs Ihs Phoenix Area |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396022026 PECOS PAC ID: 0244405629 Enrollment ID: O20120105000013 |
News Archive
Children may have a better quality of life (QOL) and diminished cardiovascular disease risk from the decreased endothelin 1 (ET-1) levels after adenotonsillectomy, according to new research published in the December 2011 issue of Otolaryngology - Head and Neck Surgery.
ARIUS Research Inc has announced that the Company has initiated the first study in the formal pre-clinical toxicology program for its lead anti-CD44 drug candidate, which is under development for the treatment of breast, prostate and liver cancers.
According to a new survey most people at high risk of Alzheimer's disease would be willing to have their loved ones enroll them in research studies when they could no longer give consent themselves.
Roche and study investigators from Harvard University and Massachusetts General Hospital announced today that in the PROTECT (Pro-BNP Outpatient Tailored Chronic HF Therapy) trial, a strategy of NT-proBNP guided heart failure care was independently associated with a significant reduction in total cardiovascular events, the primary composite endpoint of the study, which included worsening heart failure, heart failure hospitalization and cardiovascular related death
Santen Pharmaceutical Co., Ltd. and Inspire Pharmaceuticals, Inc. announced today that the Japanese Ministry of Health, Labour and Welfare granted approval for the new dry eye treatment drug, DIQUAS Ophthalmic Solution 3% (generic name: diquafosol tetrasodium), on April 16, 2010.
› Verified 5 days ago
| Entity Name | Dhhs Ihs Phoenix Area |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1265719934 PECOS PAC ID: 7810163011 Enrollment ID: O20120109000961 |
News Archive
Children may have a better quality of life (QOL) and diminished cardiovascular disease risk from the decreased endothelin 1 (ET-1) levels after adenotonsillectomy, according to new research published in the December 2011 issue of Otolaryngology - Head and Neck Surgery.
ARIUS Research Inc has announced that the Company has initiated the first study in the formal pre-clinical toxicology program for its lead anti-CD44 drug candidate, which is under development for the treatment of breast, prostate and liver cancers.
According to a new survey most people at high risk of Alzheimer's disease would be willing to have their loved ones enroll them in research studies when they could no longer give consent themselves.
Roche and study investigators from Harvard University and Massachusetts General Hospital announced today that in the PROTECT (Pro-BNP Outpatient Tailored Chronic HF Therapy) trial, a strategy of NT-proBNP guided heart failure care was independently associated with a significant reduction in total cardiovascular events, the primary composite endpoint of the study, which included worsening heart failure, heart failure hospitalization and cardiovascular related death
Santen Pharmaceutical Co., Ltd. and Inspire Pharmaceuticals, Inc. announced today that the Japanese Ministry of Health, Labour and Welfare granted approval for the new dry eye treatment drug, DIQUAS Ophthalmic Solution 3% (generic name: diquafosol tetrasodium), on April 16, 2010.
› Verified 5 days ago
| Entity Name | Dhhs Ihs Phoenix Area |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427335140 PECOS PAC ID: 2668649567 Enrollment ID: O20120117000781 |
News Archive
Children may have a better quality of life (QOL) and diminished cardiovascular disease risk from the decreased endothelin 1 (ET-1) levels after adenotonsillectomy, according to new research published in the December 2011 issue of Otolaryngology - Head and Neck Surgery.
ARIUS Research Inc has announced that the Company has initiated the first study in the formal pre-clinical toxicology program for its lead anti-CD44 drug candidate, which is under development for the treatment of breast, prostate and liver cancers.
According to a new survey most people at high risk of Alzheimer's disease would be willing to have their loved ones enroll them in research studies when they could no longer give consent themselves.
Roche and study investigators from Harvard University and Massachusetts General Hospital announced today that in the PROTECT (Pro-BNP Outpatient Tailored Chronic HF Therapy) trial, a strategy of NT-proBNP guided heart failure care was independently associated with a significant reduction in total cardiovascular events, the primary composite endpoint of the study, which included worsening heart failure, heart failure hospitalization and cardiovascular related death
Santen Pharmaceutical Co., Ltd. and Inspire Pharmaceuticals, Inc. announced today that the Japanese Ministry of Health, Labour and Welfare granted approval for the new dry eye treatment drug, DIQUAS Ophthalmic Solution 3% (generic name: diquafosol tetrasodium), on April 16, 2010.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dianna Lynn Mahoney, MD Po Box 860, Whiteriver, AZ 85941-0860 Ph: (928) 338-4911 | Dianna Lynn Mahoney, MD 200 W. Hospital Drive, Whiteriver, AZ 85941-0860 Ph: (928) 338-4911 |
News Archive
Children may have a better quality of life (QOL) and diminished cardiovascular disease risk from the decreased endothelin 1 (ET-1) levels after adenotonsillectomy, according to new research published in the December 2011 issue of Otolaryngology - Head and Neck Surgery.
ARIUS Research Inc has announced that the Company has initiated the first study in the formal pre-clinical toxicology program for its lead anti-CD44 drug candidate, which is under development for the treatment of breast, prostate and liver cancers.
According to a new survey most people at high risk of Alzheimer's disease would be willing to have their loved ones enroll them in research studies when they could no longer give consent themselves.
Roche and study investigators from Harvard University and Massachusetts General Hospital announced today that in the PROTECT (Pro-BNP Outpatient Tailored Chronic HF Therapy) trial, a strategy of NT-proBNP guided heart failure care was independently associated with a significant reduction in total cardiovascular events, the primary composite endpoint of the study, which included worsening heart failure, heart failure hospitalization and cardiovascular related death
Santen Pharmaceutical Co., Ltd. and Inspire Pharmaceuticals, Inc. announced today that the Japanese Ministry of Health, Labour and Welfare granted approval for the new dry eye treatment drug, DIQUAS Ophthalmic Solution 3% (generic name: diquafosol tetrasodium), on April 16, 2010.
› Verified 5 days ago
Christopher K Jentoft, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 200 West Hospital Drive, Whiteriver, AZ 85941 Phone: 928-338-4911 Fax: 928-338-3520 | |
Dr. Pattie Jean Malone, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 200 W. Hospital Drive, Whiteriver, AZ 85941 Phone: 928-338-4911 | |
Dr. James George Ard, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 200 W Hospital Dr, Whiteriver, AZ 85941 Phone: 928-338-4911 Fax: 928-338-5508 | |
Dr. David Alan Yost, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 200 West Hospital Drive, Whiteriver, AZ 85941 Phone: 928-338-4911 Fax: 928-338-3522 | |
Dr. John Christian Umhau, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 200 West Hospital Dr, Whiteriver, AZ 85941 Phone: 928-338-3555 Fax: 928-338-5508 | |
Dr. John S Condojani, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 200 W. Hospital Dr, Whiteriver, AZ 85941 Phone: 928-338-4911 | |
Edgar Alan Boone, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 200 West Hospital Drive, Whiteriver, AZ 85941 Phone: 928-338-4911 Fax: 928-338-5508 |